Rankings
▼
Calendar
VRTX Q1 2025 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
VRTX
Vertex Pharmaceuticals Incorporated
$129B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2.8B
+3.1% YoY
Gross Profit
$2.4B
86.9% margin
Operating Income
$630M
22.7% margin
Net Income
$646M
23.3% margin
EPS (Diluted)
$2.49
QoQ Revenue Growth
-4.9%
Cash Flow
Operating Cash Flow
$819M
Free Cash Flow
$778M
Stock-Based Comp.
$166M
Balance Sheet
Total Assets
$22.9B
Total Liabilities
$6.4B
Stockholders' Equity
$16.5B
Cash & Equivalents
$4.7B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2.8B
$2.7B
+3.1%
Gross Profit
$2.4B
$2.3B
+2.7%
Operating Income
$630M
$1.1B
-44.7%
Net Income
$646M
$1.1B
-41.2%
Revenue Segments
TRIKAFTA/KAFTRIO
$2.5B
92%
Manufactured Product, Other
$171M
6%
ALYFTREK
$54M
2%
Geographic Segments
UNITED STATES
$1.7B
60%
Europe
$827M
30%
Other, Non U.S.
$280M
10%
← FY 2025
All Quarters
Q2 2025 →